ANGPTL7, a therapeutic target for increased intraocular pressure and glaucoma

Adult Mice, Knockout QH301-705.5 Glaucoma Blindness Article Mice 03 medical and health sciences Angiopoietin-like Proteins 0302 clinical medicine Animals Humans Biology (General) Angiopoietin-Like Protein 7 Intraocular Pressure
DOI: 10.1038/s42003-022-03932-6 Publication Date: 2022-10-03T12:03:17Z
AUTHORS (168)
ABSTRACT
Glaucoma is a leading cause of blindness. Current glaucoma medications work by lowering intraocular pressure (IOP), risk factor for glaucoma, but most treatments do not directly target the pathological changes to increased IOP, which can manifest as medication resistance disease progresses. To identify physiological modulators we performed genome- and exome-wide association analysis in >129,000 individuals with IOP measurements extended these findings an risk. We report identification functional characterization rare coding variants (including loss-of-function variants) ANGPTL7 associated reduction protection. validated human genetics mice establishing that Angptl7 knockout have lower (~2 mmHg) basal compared wild-type, trend towards also heterozygotes. Conversely, increasing murine levels via injection into mouse eyes increases IOP. show acute silencing adult lowers (~2-4 mmHg), reproducing observations mice. Collectively, our data suggest important homeostasis amenable therapeutic modulation help maintain healthy prevent onset or slow progression glaucoma.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (58)
CITATIONS (15)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....